title: Association among EPHB2, TrkA, and MYCN expression in low-stage neuroblastomas.
abstract: BACKGROUND
  The EPH family is the largest subfamily of receptor protein-tyrosine kinases, consisting of EPHA and EPHB subgroups. Ligands of EPH family receptors are called ephrins, which include ephrin-A and ephrin-B subgroups. We recently found that transcripts encoding the EPHB subgroup (EPHB) and the ephrin-B subgroup (EFNB) were expressed together in neuroblastoma (NB) cell lines.
  
  
  METHODS
  In this study, we examined the expression of EPHB and EFNB transcripts in 24 NB specimens representing all clinical stages. We found that several EPHB and EFNB transcripts were expressed together in all NBs examined.
  
  
  RESULTS
  Among the transcripts examined, EPHB6 expression was most significantly associated with low stage tumors (stages 1, 2, and 4S; P = 0.0048). TrkA expression was significantly correlated with EPHB6, EFNB2, and EFNB3 expression (P < 0.01 in each case). Taken together, these data indicate that the expression of EPHB6, EFNB2, and EFNB3 may serve as prognostic indicators of favorable NBs. In the low-stage NBs without MYCN amplification, EPHB2 expression was correlated both with MYCN expression and with TrkA expression (P < 0.01 in each case). Moreover, MYCN expression was correlated with TrkA expression (P < 0.01) in the low-stage NBs.
  
  
  CONCLUSIONS
  This observation points to the possibility that MYCN expression might contribute to favorable outcome of low-stage NBs.
authors.affiliation: Division of Oncology, Children's Hospital of Philadelphia, Pennsylvania 19104-4318, USA.
authors.forename: X X
authors.initials: XX
authors.lastname: Tang
authors.forename: A E
authors.initials: AE
authors.lastname: Evans
authors.forename: H
authors.initials: H
authors.lastname: Zhao
authors.forename: A
authors.initials: A
authors.lastname: Cnaan
authors.forename: G M
authors.initials: GM
authors.lastname: Brodeur
authors.forename: N
authors.initials: N
authors.lastname: Ikegaki
mesh_terms: D015972:Gene Expression Regulation, Neoplastic; D016259:Genes, myc; D006801:Humans; D009363:Neoplasm Proteins / Q000096:biosynthesis* / Q000235:genetics; D009367:Neoplasm Staging; D009447:Neuroblastoma / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D011379:Prognosis; D016271:Proto-Oncogene Proteins c-myc / Q000096:biosynthesis*; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D012334:RNA, Neoplasm / Q000096:biosynthesis / Q000235:genetics; D020794:Receptor Protein-Tyrosine Kinases / Q000096:biosynthesis* / Q000235:genetics; D036183:Receptor, EphB2; D020917:Receptor, trkA / Q000096:biosynthesis* / Q000235:genetics
chemical_list: D009363:Neoplasm Proteins; D016271:Proto-Oncogene Proteins c-myc; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D020794:Receptor Protein-Tyrosine Kinases; D036183:Receptor, EphB2; D020917:Receptor, trkA